Venn has a 15-year track record in offering PMx programming and translational modelling and simulation (M&S) services to the pharmaceutical industry. We are the preferred partner in clinical pharmacology to major pharma for both FSP and project-based engagements. 

We integrate quality at every stage of product and service development. Our experience in navigating the complex regulatory landscape ensures that your processes align with current standards, and you are prepared for the foreseeable future demands.

Venn Life Sciences, part of the hVIVO plc, is an Integrated Drug/ATMP Development Partner offering a unique combination of pre-clinical/CMC development expertise, clinical trial design and management. That enables to create, plan, and execute the development programs effectively and seamlessly for the clients.

Venn provides data-centric End-to-End Trial Support, providing data driven trial design and methodology. The Service Sheet describes where Venn designed a single seamless phase II/III adaptive pivotal study, supporting the marketing authorisation application for a product in a high unmet medical need in a pediatric indication.

For over 25 years, the clinical pharmacokinetic (PK) and pharmacodynamic (PD) team of Venn Life Sciences have supported (model-independent) noncompartmental (NCA) PK and PD analyses for top ten pharmaceutical companies.

The CMC regulatory team has 20+ years’ experience supporting several pharma (small and large molecules) and medical device companies to ensure the continual manufacture and supply of high quality products to patients in licenced global markets.

Small dedicated team of Senior Medical Writers and Clinical Trial Assistant with total team experience in clinical and regulatory writing of more than 75 years.

Venn clinical trial management group has the expertise to set-up, coordinate and deliver clinical trials including vendor selection, investigational product logistics, data management, safety analyses, reporting, and clinical monitoring. We have experience with chemical entities, vaccines, and generic compounds.